Source BioScience UK has acquired clinical healthcare testing service provider Cambridge Clinical Laboratories (CCL), enhancing its clinical diagnostics portfolio.
The acquisition enables Source BioScience to leverage the expertise of the CCL team and the new clinical lab facilities at Vision Park in Cambridge, offering “streamlined” testing services for both preclinical and clinical research.
Go deeper with GlobalData
The financial aspects of the acquisition remain undisclosed.
CCL is claimed to offer “personalised” healthcare diagnostic services, covering oncology, virology, and fertility. It also provides validation studies for clinical research, serving the National Health Service (NHS) and international private clients.
According to Source BioScience, the acquisition is set to “complement” its genomics and multiomics capabilities, broadening its clinical offerings.
This includes molecular diagnostics, clinical study support, and digital pathology, aiming to offer a full lab service portfolio.
By providing end-to-end testing solutions, researchers can advance candidates through research and development (R&D) to preclinical and clinical phases with a single outsourcing partner, stated Source BioScience.
This approach reduces resource demands and data bias throughout the development process while also allowing for extra support in clinical research and diagnostics.
CCL’s complete assets and staff are set to move to the new clinical facilities at the current Source Genomics site in Vision Park.
The expanded lab footprint will allow the company to increase the capacity of current services and aid in exploring new offerings for future projects.
The site will also foster partnerships between the genomics and clinical services teams to offer customers deeper insights into their data.
Source BioScience chairman and CEO Jay LeCoque said: “We’re extremely pleased to welcome CCL into our team here at Source Bioscience.
“By investing in a new clinical lab facility and bringing in the talented team at CCL, we will open up significant new market opportunities in clinical diagnostics and be able to support our customers through all stages of their programmes.”
Comprising Source Genomics and Source LDPath, Source BioScience is a provider of lab services in multiomics, genomics, and healthcare diagnostics.
The company collaborates with entities across the pharmaceutical, healthcare, biotechnology, and academic sectors.
